Literature DB >> 28341246

Anemone rivularis inhibits pyruvate dehydrogenase kinase activity and tumor growth.

Tae-Wook Chung1, Jung Hee Lee1, Hee-Jung Choi1, Mi-Ju Park1, Eun-Yeong Kim1, Jung Ho Han1, Se Bok Jang2, Syng-Ook Lee3, Sang Woo Lee4, Jin Hang5, Li Wan Yi5, Ki-Tae Ha6.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Anemone rivularis Buch.-Ham. ex DC. (Ranunculaceae) have been used as a traditional remedy for treatment of inflammation and cancer. However, there is no report demonstrating experimental evidence on anti-tumor action of A. rivularis.
AIM OF STUDY: The Warburg's effect, preference of aerobic glycolysis rather than oxidative phosphorylation (OXPHOS) even in oxygen rich condition, is focused as one of major characteristics of malignant tumor. Thus, we investigated the effect of A. rivularis on the Pyruvate dehydrogenase (PDH) kinases (PDHKs), a major molecular targets for reducing aerobic glycolysis.
MATERIALS AND METHODS: The ethanol extract of whole plant of A. rivularis (ARE), fingerprinted by high performance liquid chromatography (HPLC), was applied to in vitro and cell-based PDHK activity assays. The effect of ARE on cell viabilities of several tumor cells was estimated by MTT assay. The expression of phosphor-PDH, PDH and PDHK1 were measured by Western blot analysis. The production of reactive oxygen species (ROS) and apoptosis was measured by fluorescence-activated cell sorting analysis, using 5-(and-6)-carboxy-2',7'-dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA) and Annexin V/propidium iodide (PI) staining, respectively. Mitochondrial membrane potential was examined by tetramethylrhodamine methyl ester (TMRM) staining. In vivo anti-tumor efficacy of ARE was estimated by means of tumor volume and weight using allograft injection of murine Lewis lung carcinoma (LLC) cells to dorsa of C57BL/6 mice.
RESULTS: ARE inhibited the viabilities of several cancer cells, including MDA-MB321, K562, HT29, Hep3B, DLD-1, and LLC. ARE suppressed PDHK activity in in vitro kinase assay, and also inhibited aerobic glycolysis by reducing phosphorylation of PDHA in human DLD-1 colon cancer and murine LLC cells. The expression of PDHK1, a major isoform of PDHKs in cancer, was not affected by ARE treatment. Moreover, ARE increased the both ROS production and mitochondrial damage. In addition, ARE suppressed the in vitro tumor growth through mitochondria-mediated apoptosis. The growth rates of allograft LLC cells were also reduced by ARE treatment.
CONCLUSIONS: Here, we firstly report that ARE inhibits PDHK activity and growth of tumor in both in vitro and in vivo experiments. Therefore, we suggest ARE as a potential candidate for developing anti-cancer drugs.
Copyright © 2017 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Anemone rivularis; Apoptosis; Mitochondria; Pyruvate dehydrogenase kinase; Warburg's effect

Mesh:

Substances:

Year:  2017        PMID: 28341246     DOI: 10.1016/j.jep.2017.03.034

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  3 in total

1.  Hemistepsin A suppresses colorectal cancer growth through inhibiting pyruvate dehydrogenase kinase activity.

Authors:  Ling Jin; Eun-Yeong Kim; Tae-Wook Chung; Chang Woo Han; So Young Park; Jung Ho Han; Sung-Jin Bae; Jong Rok Lee; Young Woo Kim; Se Bok Jang; Ki-Tae Ha
Journal:  Sci Rep       Date:  2020-12-14       Impact factor: 4.379

2.  Ilimaquinone Induces the Apoptotic Cell Death of Cancer Cells by Reducing Pyruvate Dehydrogenase Kinase 1 Activity.

Authors:  Choong-Hwan Kwak; Ling Jin; Jung Ho Han; Chang Woo Han; Eonmi Kim; MyoungLae Cho; Tae-Wook Chung; Sung-Jin Bae; Se Bok Jang; Ki-Tae Ha
Journal:  Int J Mol Sci       Date:  2020-08-21       Impact factor: 5.923

Review 3.  Unravelling the Anticancer Mechanisms of Traditional Herbal Medicines with Metabolomics.

Authors:  Omolola R Oyenihi; Ayodeji B Oyenihi; Joseph O Erhabor; Motlalepula G Matsabisa; Oluwafemi O Oguntibeju
Journal:  Molecules       Date:  2021-10-29       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.